Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience

Abstract Immunotherapy with anti-PD-1 antibodies significantly improved the prognosis in advanced melanoma patients, but most of them develop primary or secondary resistance to the treatment. In this study, we evaluated efficacy and safety of a chemotherapy regimen with weekly carboplatin plus pacli...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Francesca Romana Di Pietro, Daniele Marinelli, Sofia Verkhovskaia, Giulia Poti, Rosa Falcone, Maria Luigia Carbone, Maria Francesca Morelli, Albina Rita Zappalà, Zorika Christiana Di Rocco, Roberto Morese, Gabriele Piesco, Paolo Chesi, Paolo Marchetti, Cristina Maria Failla, Federica De Galitiis
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2024-10-01
Rangatū:	BMC Cancer
Ngā marau:	Melanoma Immunoresistance Platinum-based chemotherapy Palliative treatment
Urunga tuihono:	https://doi.org/10.1186/s12885-024-12961-9
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!